Although administration of BRAF inhibitors such as vemurafenib has shown promising results for RAI-refractory thyroid cancers, the occurrence of adverse effects and primary and/or acquired resistance often limit its applicability for targeted therapy 59. Here, BRAF is linked to thyroid gland carcinoma.